BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy

Sandro Malacrida, Simona Agata, Monia Callegaro, Cinzia Casella, Daniela Barana, Maria C. Scaini, Siranoush Manoukian, Cristina Oliani, Paolo Radice, Monica Barile, Chiara Menin, Emma D'Andrea, Marco Montagna

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: A growing number of sequence changes of unknown clinical significance are being identified in the BRCA1 gene. However, these variants cannot be used for identification and surveillance of at-risk individuals unless their pathogenic role can be demonstrated. The frequency of these variants makes research on this subject a relevant topic in the field of predisposition to breast and ovarian cancers. Herein, we investigate the pathogenicity of the BRCA1 p.Val1688del (c.5181_5183delGTT) variant, which recurs in our population. Patients and Methods: Recent studies have drawn attention to different strategies that, if considered singly, do not usually provide sufficient power to firmly state for or against causality, thus forcing to a re-evaluation of the literature on each specific variant. To increase the power of our study, we used a recently described strategy that integrates data from multiple independent evidences. By this approach, we analyzed data from the comprehensive study of 12 breast/ovarian cancer families carrying p.Val1688del. Results: We succeeded in integrating five independent evidences of disease causality including segregation, tumor pathology, and evolutionary and epidemiologic data. Under this model, we obtained a final score of 349,000:1 in favor of disease causality. This result largely matches established cutoffs, and thus is readily translatable into a clear clinical message. Conclusion: We show that p.Val1688del is a pathogenic mutation deriving from a common founder. Notably, this study alone increases by 15% the number of BRCA1-positive families in our patients' cohort, thus substantially contributing to explain many of the families wherein prediction of a BRCA1 mutation contrasted with the absence of a molecular recognizable defect.

Original languageEnglish
Pages (from-to)26-31
Number of pages6
JournalJournal of Clinical Oncology
Volume26
Issue number1
DOIs
Publication statusPublished - Jan 1 2008

Fingerprint

Causality
Ovarian Neoplasms
Italy
Breast Neoplasms
Mutation
BRCA1 Gene
Virulence
Pathology
Research
Population
Neoplasms
Identification (Psychology)
Power (Psychology)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy. / Malacrida, Sandro; Agata, Simona; Callegaro, Monia; Casella, Cinzia; Barana, Daniela; Scaini, Maria C.; Manoukian, Siranoush; Oliani, Cristina; Radice, Paolo; Barile, Monica; Menin, Chiara; D'Andrea, Emma; Montagna, Marco.

In: Journal of Clinical Oncology, Vol. 26, No. 1, 01.01.2008, p. 26-31.

Research output: Contribution to journalArticle

Malacrida, Sandro ; Agata, Simona ; Callegaro, Monia ; Casella, Cinzia ; Barana, Daniela ; Scaini, Maria C. ; Manoukian, Siranoush ; Oliani, Cristina ; Radice, Paolo ; Barile, Monica ; Menin, Chiara ; D'Andrea, Emma ; Montagna, Marco. / BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 1. pp. 26-31.
@article{fa5f497b68194352b0d0a9ebf16d4b3a,
title = "BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy",
abstract = "Purpose: A growing number of sequence changes of unknown clinical significance are being identified in the BRCA1 gene. However, these variants cannot be used for identification and surveillance of at-risk individuals unless their pathogenic role can be demonstrated. The frequency of these variants makes research on this subject a relevant topic in the field of predisposition to breast and ovarian cancers. Herein, we investigate the pathogenicity of the BRCA1 p.Val1688del (c.5181_5183delGTT) variant, which recurs in our population. Patients and Methods: Recent studies have drawn attention to different strategies that, if considered singly, do not usually provide sufficient power to firmly state for or against causality, thus forcing to a re-evaluation of the literature on each specific variant. To increase the power of our study, we used a recently described strategy that integrates data from multiple independent evidences. By this approach, we analyzed data from the comprehensive study of 12 breast/ovarian cancer families carrying p.Val1688del. Results: We succeeded in integrating five independent evidences of disease causality including segregation, tumor pathology, and evolutionary and epidemiologic data. Under this model, we obtained a final score of 349,000:1 in favor of disease causality. This result largely matches established cutoffs, and thus is readily translatable into a clear clinical message. Conclusion: We show that p.Val1688del is a pathogenic mutation deriving from a common founder. Notably, this study alone increases by 15{\%} the number of BRCA1-positive families in our patients' cohort, thus substantially contributing to explain many of the families wherein prediction of a BRCA1 mutation contrasted with the absence of a molecular recognizable defect.",
author = "Sandro Malacrida and Simona Agata and Monia Callegaro and Cinzia Casella and Daniela Barana and Scaini, {Maria C.} and Siranoush Manoukian and Cristina Oliani and Paolo Radice and Monica Barile and Chiara Menin and Emma D'Andrea and Marco Montagna",
year = "2008",
month = "1",
day = "1",
doi = "10.1200/JCO.2007.13.2118",
language = "English",
volume = "26",
pages = "26--31",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy

AU - Malacrida, Sandro

AU - Agata, Simona

AU - Callegaro, Monia

AU - Casella, Cinzia

AU - Barana, Daniela

AU - Scaini, Maria C.

AU - Manoukian, Siranoush

AU - Oliani, Cristina

AU - Radice, Paolo

AU - Barile, Monica

AU - Menin, Chiara

AU - D'Andrea, Emma

AU - Montagna, Marco

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Purpose: A growing number of sequence changes of unknown clinical significance are being identified in the BRCA1 gene. However, these variants cannot be used for identification and surveillance of at-risk individuals unless their pathogenic role can be demonstrated. The frequency of these variants makes research on this subject a relevant topic in the field of predisposition to breast and ovarian cancers. Herein, we investigate the pathogenicity of the BRCA1 p.Val1688del (c.5181_5183delGTT) variant, which recurs in our population. Patients and Methods: Recent studies have drawn attention to different strategies that, if considered singly, do not usually provide sufficient power to firmly state for or against causality, thus forcing to a re-evaluation of the literature on each specific variant. To increase the power of our study, we used a recently described strategy that integrates data from multiple independent evidences. By this approach, we analyzed data from the comprehensive study of 12 breast/ovarian cancer families carrying p.Val1688del. Results: We succeeded in integrating five independent evidences of disease causality including segregation, tumor pathology, and evolutionary and epidemiologic data. Under this model, we obtained a final score of 349,000:1 in favor of disease causality. This result largely matches established cutoffs, and thus is readily translatable into a clear clinical message. Conclusion: We show that p.Val1688del is a pathogenic mutation deriving from a common founder. Notably, this study alone increases by 15% the number of BRCA1-positive families in our patients' cohort, thus substantially contributing to explain many of the families wherein prediction of a BRCA1 mutation contrasted with the absence of a molecular recognizable defect.

AB - Purpose: A growing number of sequence changes of unknown clinical significance are being identified in the BRCA1 gene. However, these variants cannot be used for identification and surveillance of at-risk individuals unless their pathogenic role can be demonstrated. The frequency of these variants makes research on this subject a relevant topic in the field of predisposition to breast and ovarian cancers. Herein, we investigate the pathogenicity of the BRCA1 p.Val1688del (c.5181_5183delGTT) variant, which recurs in our population. Patients and Methods: Recent studies have drawn attention to different strategies that, if considered singly, do not usually provide sufficient power to firmly state for or against causality, thus forcing to a re-evaluation of the literature on each specific variant. To increase the power of our study, we used a recently described strategy that integrates data from multiple independent evidences. By this approach, we analyzed data from the comprehensive study of 12 breast/ovarian cancer families carrying p.Val1688del. Results: We succeeded in integrating five independent evidences of disease causality including segregation, tumor pathology, and evolutionary and epidemiologic data. Under this model, we obtained a final score of 349,000:1 in favor of disease causality. This result largely matches established cutoffs, and thus is readily translatable into a clear clinical message. Conclusion: We show that p.Val1688del is a pathogenic mutation deriving from a common founder. Notably, this study alone increases by 15% the number of BRCA1-positive families in our patients' cohort, thus substantially contributing to explain many of the families wherein prediction of a BRCA1 mutation contrasted with the absence of a molecular recognizable defect.

UR - http://www.scopus.com/inward/record.url?scp=37849010906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37849010906&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.13.2118

DO - 10.1200/JCO.2007.13.2118

M3 - Article

C2 - 18165637

AN - SCOPUS:37849010906

VL - 26

SP - 26

EP - 31

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -